It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical Oncology annual meeting this year.
May 21, 2026 11:39 AM EDT
R&DChina
China’s drugmakers to take the stage at ASCO
Lei Lei Wu
News Reporter
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
EU and US advisers split over AstraZeneca breast cancer drug
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the…
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann | Each…
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
